HC Wainwright

Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) shares have gained about 46% year-to-date.  With the average analyst target being $8.42, the shares are primed for further upside provided upcoming catalysts pan out in favor of the company. Benzinga is profiling Nabriva for the benefit...

After initial hiccups such as a tough FDA panel briefing document and a not-so-favorable panel verdict, Karyopharm Therapeutics Inc (NASDAQ: KPTI) managed to secure approval for its multiple myeloma treatment Xpovio three days ahead of the given PDUFA date. The Analyst H.C. Wainwright analyst...

G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed...

Applied Genetic Technologies Corp (NASDAQ: AGTC), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis clinical study. The company also confirmed Biogen Inc (NASDAQ: BIIB) terminated...

Viking Therapeutics Inc (NASDAQ: VKTX), which focuses on therapies for metabolic and endocrine disorders, recently presented Phase 2 data for its non-alcoholic fatty liver disease, or NAFLD, treatment candidate VK2809 at the annual meeting of the American Association for the Study of Liver...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) have dropped by about 12 percent since the company reported third-quarter results Nov. 8. Analysts at HC Wainwright and Canaccord Genuity consider the sell-off an overreaction and issued positive updates on the company this week.  The Analysts HC...

CELYAD SA/ADR (NASDAQ: CYAD) bolstered its entirely bullish cohort of analysts Monday with a fresh buyer. The Rating HC Wainwright analyst Edward White initiated coverage of Celyad with a Buy rating and $45 price target. The Thesis The chimeric antigen receptor therapy, or CAR-T,  ...

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...

Cesca Therapeutics Inc (NASDAQ: KOOL) is poised to make much headway with its automated CAR-T manufacturing platform CAR-TXpress, according to H.C. Wainwright.  CAR-T-cell therapy is a method of treating cancer by using a patient's immune system cells —  T cells —...

Jounce Therapeutics Inc (NASDAQ: JNCE) shares are tumbling Thursday in reaction to the abstract data for JTX-2011 that was made available in advance of an American Society of Clinical Oncology presentation.  JTX-2011, the company's lead product candidate, is a monoclonal antibody that...

Aerpio Pharmaceuticals Inc (OTC: ARPO), an OTC-listed company specializing in drug development for ocular diseases, earned a bullish review Wednesday. The interest in the stock can only go higher, as the company seeks to up-list the shares on the Nasdaq in the coming months, according to H.C....

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts echoed investor enthusiasm, with H.C. Wainwright increasing its price target from $6.70 to $8...

Palatin Technologies, Inc. (NYSE: PTN), a biopharmaceutical company that focuses on treatments for diseases with significant unmet medical needs, boasts a lead asset, bremelanotide, that has an "arousing number of major boxes checked," according to H.C. Wainwright. The Analyst H.C....

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments. The stock could see significant upside if later-stage bladder cancer trials set for mid-2018 prove to...

The U.S. Food and Drug Administration sent an unfavorable Complete Response Letter last week to Agile Therapeutics Inc (NASDAQ: AGRX) regarding approval for the Twirla contraceptive patch. The letter also included concerns at a third-party manufacturer, Corium International Inc (NASDAQ: CORI...